Moje portfolio
Oblíbené tituly
select
NameBest
buy
Best
sell
Change
(%)
ČEZ12101211-2.97
KB994.5995.50.96
PKN140.92141-3.98
Msft398.21398.30.00
Nokia13.07513.091.32
IBM278.01278.50.00
Mercedes-Benz Group AG49.5749.5753.23
PFE26.1226.220.00
15/06/2026 10:27:55
Indices online
AD index online
select
AD index online
Patria Direct
Patria DirectThings our clients appreciate most: A large and experienced team of professional brokers, customer care support, stable and secure trading platform, unique news and information service. Try our demo account and see for yourself.

Free services: Patria Plus news services, analytical reports, account opening and keeping, submitting and cancelling orders, FX conversions. Moreover, for active traders we also offer free real-time data and Investor Plus services.
 

  • 26/05/2026 16:42:50
Sopharma AD Sofia, Ordinary, MiFID Eligible Security, Warsaw Stock Exchange (3JR.F, Frankfurt)
Last trade Change (%) Change (EUR) Turnover (EUR)
1.81 0.00 0.00 1,810
R - Real-Time data can be activated by Patria Plus / Investor Plus clients HERE.

 
  • Latest update: 15/06/2026
Company description
General information
Company nameSopharma AD
TickerSFA
Ordinary sharesOrdinary Shares
RICBGSFA.BB
ISINBG11SOSOBT18
Last annual results31/12/2025
Last interim results31/03/2026
Number of emploees as of 31/03/2026 6 005
Shares outstanding as of 31/03/2026 528 433 603
CurrencyEUR
Contact information
Streetrayon Nadezhda, ul. Iliensko Shose No16
CitySOFIA
Zip code1220
CountryBulgaria
Contact person 
Function of contact person 
Phone35 928 134 200
Fax35928134141

Business Summary: Sopharma AD, formerly Sopharma AD Sofia, is a Bulgaria-based company engaged in the generic pharmaceutical industry. The Company specializes in the production and trade of medical substances and finished drug forms, as well as research and development in the field of medical products. Through the ampoule plant, tablet plant and the plant in Vrabevo it produces medicines, such as analgesics, antipyretics, cardiovascular medicines as well as drugs for respiratory disease treatment, among others. The Company offers its products under the brand Tribestan, Nivalin and Tabex, among others. In addition, it specializes in the gamma-sterilization of medical materials. It is the parent company of Sopharma Group and operates domestically and abroad in such countries as Russian Federation, Poland, Ukraine, Serbia, the United States and the United Kingdom, among others.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Sopharma AD revenues totaled EUR360.6M. Net income totaled to EUR31.7M. Results are not comparable due to currency change.
Sector classification
TRBC2009Retail - Drugs
TRBC2012Drug Retailers (NEC)
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYRetail (Drugs)
MGSECTORServices
NAICSPharmacies and Drug Retailers
NAICSPharmaceutical Preparation Manufacturing
NAICSMedicinal and Botanical Manufacturing
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSToilet Preparation Manufacturing
NAICS2007Pharmacies and Drug Stores
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Medicinal & Botanical Mfg
NAICS1997Pharmacies and Drug Stores
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Medicinal and Botanical Manufacturing
SICDrug Stores/proprietary Stores
SICPharmaceutical Preparations
SICMedicinals And Botanicals
SICBiological Prod's Not Diagnostic
SICToilet Preparations



  • Latest update: 15/06/2026
Company management
FunctionNameAgeOfficer sinceIn company since
Chairman of the Board, Chief Executive OfficerIvan Donev38
Deputy Chairman of the Board, Economic Adviser to CEOVesela Stoeva5901/01/2000
Finance DirectorBoris Borisov-
Chief AccountantYordanka Petkova58
ProcuratorSimeon Donev-
Head of Legal DepartmentAlexander Yotov-